606 related articles for article (PubMed ID: 34954493)
1. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
2. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
3. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
4. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
[TBL] [Abstract][Full Text] [Related]
7. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
8. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
9. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
[TBL] [Abstract][Full Text] [Related]
10. M
Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
[TBL] [Abstract][Full Text] [Related]
11. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
12. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
[TBL] [Abstract][Full Text] [Related]
13. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
14. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.
Handanagic S; Broz D; Finlayson T; Kanny D; Wejnert C;
Drug Alcohol Depend; 2024 Apr; 257():111251. PubMed ID: 38457965
[TBL] [Abstract][Full Text] [Related]
15. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
[No Abstract] [Full Text] [Related]
16. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder.
Pericot-Valverde I; Heo M; Niu J; Rennert L; Norton BL; Akiyama MJ; Arnsten J; Litwin AH
Drug Alcohol Depend; 2022 May; 234():109403. PubMed ID: 35306390
[TBL] [Abstract][Full Text] [Related]
17. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
[TBL] [Abstract][Full Text] [Related]
18. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
[TBL] [Abstract][Full Text] [Related]
19. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
[TBL] [Abstract][Full Text] [Related]
20. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
